Bit.bio
Human cell coding company
Bit.bio is an award-winning synthetic biology enterprise, coding human cells for health. The company's aim is to develop a platform capable of producing consistent batches of every human cell. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies.
Visit website: https://bit.bio/
Details last updated 12-Apr-2021
People at Bit.bio
Bit.bio News
Bit.bio reveals early pipeline of regenerative medicine candidates
Endpoints News - 08-Nov-2023
Lead program bbHEP01 targets severe acute liver failure, with phase I trial planned for 2025
Read more...Synthetic human cells revolution: bit.bio achieves mass production breakthrough
iNews - 15-Jun-2023
Paves way for potential medical research, organ manufacturing and disease treatment advances
Read more...Bit Bio secures $41.5 M funding to produce human cells
Biospace - 15-Jun-2020
UK-based startup reprogramming stem cells to generate new cell therapies
Read more...